

Desarrollo de Nuevos Tratamientos y Vacunas frente a SARS-CoV-2: Actualidad y Perspectivas

Dra. Cristina Rabadán-Diehl

Directora Asociada de Ensayos Clínicos. WESTAT.

Rockville, MD (EE.UU.)

CristinaRabadan-Diehl@westat.com

<https://www.westat.com/focus-area/clinical-trials>

Miércoles, 15 de abril de 2020

NEW:

Testing numbers added, US state's recovered numbers are TEMPORARILY removed.

Quick Facts

updated: a few seconds ago

2,015,571

Total Confirmed Cases

127,635

Total Deceased

16,111,428

Total Tested

491,911

Total Recovered

Go To Region

All Regions

World

USA

Europe

Asia

Africa

World COVID-19 Stats

RECOVERED: 25%

FATALITY RATE: 7%



search data

NAME	CONFIRMED	CHANGES TODAY	DECEASED	CHANGES TODAY	RECOVERED	TESTS
TOTAL	2,015,571	↑ 17,711 (0.88%)	127,635	↑ 1,035 (0.81%)	491,911	16,111,428
★ United States	614,246	↑ 360 (0.05%)	26,064	↑ 17 (0.06%)	1,868	3,100,387
★ Spain	177,633	↑ 3,573 (2.05%)	18,579	↑ 324 (1.77%)	19,259	600,000
★ Italy	162,488		21,067		15,729	1,073,689
★ France	143,303		15,729		7,928	333,807
★ Germany	132,210		3,495		15,824	1,317,887
★ United Kingdom	93,873		12,107		135	382,650
★ China	82,295	↑ 46 (0.05%)	3,342	↑ 1 (0.02%)	74,862	
★ Iran	76,389	↑ 1,512 (2.01%)	4,777	↑ 94 (2.00%)	14,656	299,204

Europe COVID-19 Stats

RECOVERED: 7%

FATALITY RATE: 9%



search data

NAME	CONFIRMED	CHANGES TODAY	DECEASED	CHANGES TODAY	RECOVERED	TESTS
TOTAL	942,948	↑ 12,194 (1.31%)	84,313	↑ 752 (0.89%)	65,467	7,327,253
★ Spain	177,633	↑ 3,573 (2.05%)	18,579	↑ 324 (1.77%)	19,259	600,000
★ Italy	162,488		21,067		15,729	1,073,689
★ France	143,303		15,729		7,928	333,807
★ Germany	132,210		3,495		15,824	1,317,887
★ United Kingdom	93,873		12,107		135	382,650

USA COVID-19 Stats

RECOVERED: 1%

FATALITY RATE: 5%



search data

NAME	CONFIRMED	CHANGES TODAY	DECEASED	CHANGES TODAY	RECOVERED	TESTS
TOTAL	614,246	↑ 360 (0.05%)	26,064	↑ 17 (0.06%)	1,868	3,100,387
★ New York	203,123		10,834		N/A	499,143
★ New Jersey	68,824		2,805		N/A	131,219
★ Massachusetts	28,163		957		N/A	126,551
★ Michigan	27,001		1,768		N/A	76,014
★ California	25,777	↑ 241 (0.94%)	789	↑ 7 (0.89%)	N/A	212,900
★ Pennsylvania	25,465		696		N/A	133,631
★ Illinois	23,247		868		N/A	110,616
★ Florida	21,628		571		N/A	205,413

Asia COVID-19 Stats

RECOVERED: 56%

FATALITY RATE: 4%




search data

NAME	CONFIRMED	CHANGES TODAY	DECEASED	CHANGES TODAY	RECOVERED	TESTS
TOTAL	150,408	↑ 1,692 (1.13%)	5,330	↑ 53 (1.00%)	82,784	1,863,639
★ China	82,295	↑ 46 (0.05%)	3,342	↑ 1 (0.02%)	74,862	
★ India	11,555	↑ 68 (0.59%)	396	↑ 3 (0.76%)	123	244,893
★ South Korea	10,591	↑ 27 (0.25%)	225	↑ 3 (1.35%)	4,528	534,552
★ Japan	8,100	↑ 215 (2.72%)	146		514	89,551
★ Pakistan	5,988	↑ 151 (2.58%)	107	↑ 11 (11.45%)	76	73,439

EE.UU. y COVID -19 (15- abril-2020)

USA COVID-19 Stats ↗						
RECOVERED: 1%						
FATALITY RATE: 5%		search data				
NAME	CONFIRMED	CHANGES TODAY	DECEASED	CHANGES TODAY	RECOVERED	TESTS
TOTAL	614,246	↑ 360 (0.05%)	26,064	↑ 17 (0.06%)	1,868	3,100,387
★ New York	203,123		10,834		N/A	499,143
★ New Jersey	68,824		2,805		N/A	131,219
★ Massachusetts	28,163		957		N/A	126,551
★ Michigan	27,001		1,768		N/A	76,014
★ California	25,777	↑ 241 (0.94%)	789	↑ 7 (0.89%)	N/A	212,900
★ Pennsylvania	25,465		696		N/A	133,631
★ Illinois	23,247		868		N/A	110,616
★ Florida	21,628		571		N/A	205,413

- Población: 331 millones
- Descentralización en la toma de decisiones (Los Estados tienen autonomia)
- Sistema de salud fragmentado
- Gran porcentaje de la población con co-morbididades (obesidad, diabetes, enfermedades cardiovasculares, respiratorias, etc.)



Alianzas público-privadas

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

*Johnson & Johnson and BARDA Together Commit More than \$1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020
Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply*

NEW BRUNSWICK, N.J., March 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company's manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The Company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.

Through a landmark new partnership, BARDA, which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, and Johnson & Johnson together have committed more than \$1 billion of investment to co-fund vaccine research, development, and clinical testing. Johnson & Johnson will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts. Separately, BARDA and the Company have provided additional funding that will enable expansion of their ongoing work to identify potential antiviral treatments against the novel coronavirus.





Lilly, NIAID to Study Baricitinib in COVID-19

Contract Pharma Staff || 04.13.20

Baricitinib's anti-inflammatory activity has been hypothesized to have a potential benefit in COVID-19

SARS-CoV-2





Programa para la aceleración de los Tratamientos para el Coronavirus (CTAP)

New FDA Program to Accelerate Coronavirus Treatments

Posted 31 March 2020 | By [Michael Mezher](#)

The US Food and Drug Administration (FDA) on Tuesday detailed a new “special emergency program” for accelerating research and development of potential treatments for coronavirus disease (COVID-19).


Details about the program come as the US faces the world’s largest COVID-19 outbreak, with Johns Hopkins University reporting more than 180,000 confirmed cases and 3,600 deaths attributed to the virus.

Under the coronavirus treatment acceleration program (CTAP), FDA says it is responding to requests from researchers and industry as rapidly as possible and by providing “ultra-rapid, interactive input on most development plans.”


Now that it has worked through the initial wave of requests, FDA says it intends to respond to developers within a day and will try to conduct trial protocol reviews in some cases within 24 hours. The agency says it is also working with other federal agencies, drugmakers and researchers to develop study protocols “that can be used across institutions and programs to streamline efforts.”



**Traditional Paradigm —
Multiple Years**



**Outbreak Paradigm —
Overlapping Phases
Shorten Development Time**



Access: Geographic spread of manufacturing and development sites and pursuit of emergency authorization before licensure

Ensayos Clínicos – COVID-19 (15-abril-2020)

www.clinicaltrials.gov

Terms	Search Results*	Entire Database**
Synonyms		
covid-19	585 studies	585 studies
SARS-CoV-2	187 studies	187 studies
2019-nCoV	32 studies	32 studies
2019 novel coronavirus	18 studies	18 studies
severe acute respiratory syndrome coronavirus 2	11 studies	11 studies

-- No studies found

* Number of studies in the search results containing the term or synonym


** Number of studies in the entire database containing the term or synonym

110 ensayos en EE.UU.

22 ensayos en España

Showing: 1-22 of 22 studies 25 ⬆ ⬇ studies per page					Download Share	
Row	Saved	Status	Study Title	Conditions	Interventions	Locations
1	☐	Recruiting	Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention	COVID-19	- Drug: Antiviral treatment and prophylaxis - Other: Standard Public Health measures	Departament de Salut Barcelona, Spain
2	☐	Recruiting NEW	Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic	COVID-19	- Drug: Hydroxychloroquine - Drug: Placebos	ISGlobal Barcelona, Spain
3	☐	Recruiting NEW	Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	COVID-19	- Drug: Tocilizumab - Drug: Hydroxychloroquine - Drug: Azithromycin	Hospital de la Santa Creu i Sant Pau Barcelona, Spain
4	☐	Not yet recruiting NEW	Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia	COVID-19	- Drug: Siltuximab - Drug: Methylprednisolone	Hospital Clínic de Barcelona Barcelona, Spain
5	☐	Not yet recruiting NEW	Clinical Trial to Evaluate the Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	COVID-19 Pneumonia	- Drug: Hidroxicloroquine - Drug: Lopinavir/ritonavir - Drug: Imatinib tablets - Drug: Baricitinib Oral Tablet	Hospital Universitario de Fuenlabrada Fuenlabrada, Madrid, Spain
6	☐	Recruiting NEW	Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury	- COVID-19 - Lung Injury	- Drug: Tacrolimus - Drug: Methylprednisolone	Hospital Universitari de Bellvitge L'Hospitalet de Llobregat, Barcelona, Spain
7	☐	Recruiting NEW	International COVID19 Clinical Evaluation Registry	COVID 19	Combination Product: Observational (registry)	Hospital Lclínico San Carlos Madrid, Spain
8	☐	Recruiting NEW	NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure	- Respiratory Failure - Covid-19	- Other: Monitoring for aggravation - Other: Evaluate HACOR score effectivity in this patients	Hospital General Universitario Morales Meseguer Murcia, Spain
9	☐	Not yet recruiting NEW	Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study	- Vascular Surgical Procedures - COVID-19 - Postoperative Complications	Procedure: Vascular surgery	Spanish Society for Angiology and Vascular Surgery Madrid, Spain
10	☐	Not yet recruiting NEW	Vitamin D on Prevention and Treatment of COVID-19	Patients Infected With COVID-19	Dietary Supplement: Vitamin D	- Universidad de Granada Granada, Andalucía, Spain - Medicine Faculty Granada, Spain
11	☐	Not yet recruiting NEW	Oropharyngeal Dysphagia in Patients With COVID-19	- Oropharyngeal Dysphagia - COVID-19 - Sars-CoV2 - Nutrition	Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)	Consorti Sanitari del Maresme (Hospital de Mataró) Mataró, Barcelona, Spain
12	☐	Not yet recruiting NEW	LunG cancer pAtients coVid19 Disease (GRAVID)	- Covid-19 - Lung Cancer		H. Universitario Quirón Dexeus Barcelona, Spain - H.U. Puerta de Hierro Madrid, Spain
13	☐	Active, not recruiting NEW	Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel	Coronavirus Infection	- Drug: Emtricitabine/tenofovir disoproxil - Drug: Hydroxychloroquine - Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo - Drug: Placebo: Hydroxychloroquine	Hospital Universitario Ramón y Cajal Madrid, Spain
14	☐	Recruiting NEW	Checkpoint Blockade in COVID-19 Pandemic	- COVID-19 - Pneumonia, Viral	- Drug: Tocilizumab - Biological: Pembrolizumab (MK-3475)	- Hospital Quirónsalud Barcelona Barcelona, Spain - Hospital de la Santa Creu i Sant Pau Barcelona, Spain - Hospital Ruber Juan Bravo Madrid, Spain (and 3 more...)
15	☐	Recruiting NEW	Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients	COVID-19	- Other: Blood and derivatives. - Drug: Standard of Care	- Hospital Clínico Universitario Lozano Blesa Zaragoza, Aragón, Spain - Hospital Universitario Severo Ochoa Leganés, Madrid, Spain - Hospital Universitario Puerta de Hierro Majadahonda Majadahonda, Madrid, Spain (and 6 more...)
16	☐	Recruiting NEW	Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19	Acute Respiratory Distress Syndrome Caused by COVID-19	Drug: Dexamethasone	- ICU, Hospital Universitari Mutua Terrassa Terrassa, Barcelona, Spain - Hospital Universitario Dr. Negrín Las Palmas de Gran Canaria, Las Palmas, Spain - Department of Anesthesia, Hospital Universitario de Cruces Barakaldo, Vizcaya, Spain (and 21 more...)

Plasma de personas convalecientes de COVID-19



JAMA doi:10.1001/jama2020.4783- 27 marzo 2020

J Clin Invest 2020; 130 (4):1545-1548- Abril 2020

Estudios clínicos para el tratamiento del COVID-19

- **Medicamentos para otros usos**

- Cloroquina e hidroxiclороquina (malaria, lupus, artritis reumatoide)
- Lopinavir/Ritonavir y otros anti-retrovirales (VIH)
- Ribavirin (infecciones respiratorias)
- Antivirales para la influenza (Oseltamivir,- no es efectivo- Umifenovir)
- Inmunomoduladores: Interferón, baricitinib, ciclosporina, etc.

- **Medicamentos en investigación**

- Remdesivir -amplio espectro, usado para el Ebola , prometedor.
- Favipiravir

- **Terapias adyuvantes**

- Corticosteroides (no se recomienda)
- Agentes inmunomoduladores
- Terapia con inmunoglobulinas

Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment

English ▼



Treatment with DAS181, a clinical-stage recombinant biologic, reduced or eliminated the need for supplemental oxygen, and improved key patient vital signs

NEWS PROVIDED BY


[Ansun Biopharma, Inc. →](#)

Apr 02, 2020, 07:00 ET

SHARE THIS ARTICLE



Ansun also announced the initiation of an additional randomized, double-blind, placebo-controlled proof-of-concept trial to determine the safety and efficacy of DAS181 for the treatment of severe COVID-19 pneumonia. This two-stage trial will initially enroll approximately 20 patients at medical centers across the United States. The Company expects to expand enrollment after an interim review of the data.



Clinical Symptoms	Mild constitutional symptoms Fever $>99.6^{\circ}\text{F}$ Dry Cough, diarrhea, headache	Shortness of Breath Hypoxia ($\text{PaO}_2/\text{FiO}_2 \leq 300\text{mmHg}$)	ARDS SIRS/Shock Cardiac Failure
Clinical Signs	Lymphopenia, increased prothrombin time, increased D-Dimer and LDH (mild)	Abnormal chest imaging Transaminitis Low-normal procalcitonin	Elevated inflammatory markers (CRP, LDH, IL-6, D-dimer, ferritin) Troponin, NT-proBNP elevation
Potential Therapies	Remdesivir, chloroquine, hydroxychloroquine, convalescent plasma transfusions		
	Reduce immunosuppression	Corticosteroids, human immunoglobulin, IL-6 inhibitors, IL-2 inhibitors, JAK inhibitors	

VACUNAS




TABLE 1 | CLINICAL-PHASE VACCINE CANDIDATES FOR COVID-19

Candidate	Vaccine characteristics	Lead developer	Status
mRNA-1273	LNP-encapsulated mRNA vaccine encoding S protein	Moderna	Phase I (NCT04283461)
Ad5-nCoV	Adenovirus type 5 vector that expresses S protein	CanSino Biologicals	Phase I (NCT04313127)
INO-4800	DNA plasmid encoding S protein delivered by electroporation	Inovio Pharmaceuticals	Phase I (NCT04336410)
LV-SMENP-DC	DCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs	Shenzhen Geno-Immune Medical Institute	Phase I (NCT04276896)
Pathogen-specific aAPC	aAPCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins	Shenzhen Geno-Immune Medical Institute	Phase I (NCT04299724)

aAPC, artificial antigen-presenting cell; CTL, cytotoxic T lymphocyte; DC, dendritic cell; LNP, lipid nanoparticle; S protein, SARS-CoV-2 spike protein. Source: ClinicalTrials.gov website; WHO.

Vaccine Platforms, Their Attributes, and the Status of Vaccine Candidates.*

Technology	Attributes				Candidates in Preclinical Development	Candidates in Phase 1
	Single Dose	Licensed Platform	Speed	Current Scale		
DNA	No	No	Fast	Medium	Inovio Pharmaceuticals Takis/Applied DNA Sciences/Evvivax Zyus Cadila	
Inactivated	No	Yes	Medium	Medium to high	Sinovac	
Live attenuated	Yes	Yes	Slow	High	Codagenix/Serum Institute of India	
Nonreplicating vector	Yes	No	Medium	High	GeoVax/BravoVax Janssen Pharmaceutical Companies University of Oxford Altimmune Greffex Vaxart ExpresS2ion	CanSino Biologics (ChiCTR2000030906)
Protein subunit	No	Yes	Medium to fast	High	WRAIR/U.S. Army Medical Research Institute of Infectious Diseases Clover Biopharmaceuticals Inc/GSK Vaxil Bio AJ Vaccines Genrex/EpiVax/University of Georgia Sanofi Pasteur Novavax Heat Biologics/University of Miami University of Queensland/GSK/ Baylor College of Medicine iBio/CC- Pharming	
Replicating viral vector	Yes	Yes	Medium	High	Zyus Cadila Institut Pasteur/Themis Tonix Pharma/Southern Research	
RNA	No	No	Fast	Low to medium	Fudan University/Shanghai JiaoTong University/RNACure Biopharma China CDC/Tongji University/Sterima Arcturus/Duke-NUS Imperial College London Curevac BioNTech/Pfizer	Moderna/NIAID (NCT04283461)
Uncertain					University of Pittsburgh University of Saskatchewan ImmunoPrecise MIGAL Galilee Research Institute Doherty Institute Tulane University	

* Attributes refer to general attributes of the platform, and assessments are not intended as inferences about a particular candidate. NIAID denotes National Institute of Allergy and Infectious Diseases, and WRAIR Walter Reed Army Institute of Research.

- Candidatos: 78
- La mayoría intenta introducir anticuerpos neutralizantes contra la proteína S, para evitar que el virus entre en las células a través del receptor ACE2
- El 72% (56) de las investigaciones son por industria privada
- El 28 % (22) por entidades académicas, sector público y organizaciones sin ánimo de lucro
- La mayoría son organizaciones pequeñas o sin mucha experiencia en fabricación de vacunas a gran escala

Hidroxicloroquina

FDA authorizes emergency use of antimalarial drugs for COVID-19

March 30, 2020



ADD TOPIC TO EMAIL ALERTS

The FDA authorized the emergency use of two antimalarial medications to treat some hospitalized patients with COVID-19.

The agency issued an Emergency Use Authorization (EAU) allowing the use of hydroxychloroquine and chloroquine products donated to the Strategic National Stockpile (SNS) to be distributed and used for adolescent and adult patients with [COVID-19](#) who have been hospitalized and who cannot be part of a clinical trial.

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Philippe Gautret ^{a, b, S}, Jean-Christophe Lagier ^{a, c, S}, Philippe Parola ^{a, b}, Van Thuan Hoang ^{a, b, d}, Line Meddeb ^a, Morgane Mailhe ^a, Barbara Doudier ^a, Johan Courjon ^{e, f, g}, Valérie Giordanengo ^h, Vera Esteves Vieira ^a, Hervé Tissot Dupont ^{a, c}, Stéphane Honoré ^{i, j}, Philippe Colson ^{a, c}, Eric Chabrière ^{a, c}, Bernard La Scola ^{a, c}, Jean-Marc Rolain ^{a, c}, Philippe Brouqui ^{a, c}, Didier Raoult ^{a, c, k} ✉

✉ [Show more](#)

<https://doi.org/10.1016/j.ijantimicag.2020.105949>

[Get rights and content](#)

Abstract

Background

Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.

Conclusion

Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.

20 pacientes

[Home](#)[About Us](#)[Working Groups](#)[Member Societies](#)[Meetings](#)[Journals](#)[Awards](#)

News & Publications

Statement on IJAA paper

Official Statement from International Society of Antimicrobial Chemotherapy (ISAC)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (Gautret P et al. PMID 32205204)

ISAC shares the concerns regarding the above article published recently in the International Journal of Antimicrobial Agents (IJAA). The ISAC Board believes the article does not meet the Society's expected standard, especially relating to the lack of better explanations of the inclusion criteria and the triage of patients to ensure patient safety.

Despite some suggestions online as to the reliability of the article's peer review process, the process did adhere to the industry's peer review rules. Given his role as Editor in Chief of this journal, Jean-Marc Rolain had no involvement in the peer review of the manuscript and has no access to information regarding its peer review. Full responsibility for the manuscript's peer review process was delegated to an Associate Editor.

Although ISAC recognises it is important to help the scientific community by publishing new data fast, this cannot be at the cost of reducing scientific scrutiny and best practices. Both Editors in Chief of our journals (IJAA and Journal of Global Antimicrobial Resistance) are in full agreement.

Andreas Voss
ISAC President

April 3rd-2020


HEALTH

FRENCH HOSPITAL STOPS HYDROXYCHLOROQUINE TREATMENT FOR COVID- 19 PATIENT OVER MAJOR CARDIAC RISK

BY **HANNAH OSBORNE** ON 4/8/20 AT 9:43 AM EDT

Fact Checker • Analysis

How false hope spread about hydroxychloroquine to treat covid-19 — and the consequences that followed



Claims about hydroxychloroquine to treat covid-19 have gained traction despite a lack of scientific evidence. How did this happen? (Elyse Samuels, Meg Kelly, Sarah Cahlan/The Washington Post)

By **Elyse Samuels** and **Meg Kelly**

April 13, 2020 at 3:00 a.m. EDT

The Washington Post
Democracy Dies in Darkness

Ads by Google

Stop seeing this ad

Why this ad? >

76° Bethesda, MD >

Mon, Apr 13, 2020


Newsweek

U.S. | World | Business | Tech & Science | Culture | Newsgeek | Sports | Health | The Debate

HEALTH

SPAIN LAUNCHES LARGE-SCALE STUDY OF HYDROXYCHLOROQUINE AND ANTIRETROVIRALS TO PREVENT COVID-19 IN HEALTH WORKERS

BY **LYDIA SMITH** ON 4/10/20 AT 12:01 PM EDT



CORONAVIRUS

La farmacéutica Novartis dona un millón de dosis de hidroxycloroquina para tratar la Covid-19



• La Agencia Española del Medicamento y Productos Sanitarios (AEMPS) gestionará la administración del fármaco a través de ensayos clínicos de distintos hospitales



La farmacéutica Novartis dona un millón de dosis de hidroxycloroquina para tratar la Covid-19 (EP)

EFE, BARCELONA 08/04/2020 22:39

La multinacional farmacéutica **Novartis** ha donado este miércoles cerca de un millón de dosis de hidroxycloroquina, que fabrica su filial Sandoz, para tratar a decenas miles de pacientes hospitalizados con la **Covid-19** en España.

Según ha informado en un comunicado la multinacional farmacéutica, que tiene su sede española en Barcelona, la donación se ha hecho en respuesta a una petición de la Agencia Española del Medicamento y Productos Sanitarios (AEMPS), que gestionará la administración del fármaco a través de ensayos clínicos de distintos hospitales de toda España.

#AloneTogether

For more info:
coronavirus.gov

